Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20583811 | 0.84 | KDM4E (0.55) | POLBKDM4EMEN1KMT2A | |
| SCHEMBL3332951 | 0.76 | NPSR1 (0.44) | SMN1; SMN2POLBACHENPSR1MEN1 | |
| SCHEMBL22291055 | 0.75 | GAA (0.42) | SMN1; SMN2EPHX1GAAALDH1A1 | |
| SCHEMBL22291056 | 0.75 | GAA (0.42) | SMN1; SMN2EPHX1GAAALDH1A1 | |
| SCHEMBL26621560 | 0.75 | GAA (0.42) | SMN1; SMN2EPHX1GAAALDH1A1 | |
| SCHEMBL26963280 | 0.72 | EPHX2 (0.33) | — | |
| SCHEMBL27125182 | 0.72 | EPHX2 (0.33) | — | |
| SCHEMBL17781920 | 0.71 | APLNR (0.37) | CYP2C9EPHX1MEN1KMT2AGAA | |
| SCHEMBL23443581 | 0.71 | KDM4E (0.65) | SMN1; SMN2KDM4EKMT2AGAAALDH1A1 | |
| SCHEMBL17981259 | 0.70 | EPHX2 (0.38) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826351-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230372298-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20220062239-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2022-03-03 | — | — | US | disclosed |
| US-20210093611-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3782994-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | Loxo Oncology, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10918622-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| EP-3390395-B1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY INC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20200276162-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2020-09-03 | — | — | US | disclosed |
| US-10695323-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10464905-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10342780-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190135762-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20190000806-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20180362512-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2018-12-20 | — | — | US | disclosed |
| EP-3390395-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | Loxo Oncology Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017103611-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | REDX PHARMA PLC (GB) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062239-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | CYP2C9 2791/4885CCR1 2229/4885SMN1; SMN2 4715/4885 |
| US-20180362512-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | CYP2C9 2791/4885CCR1 2229/4885SMN1; SMN2 4715/4885 |
| US-20190135762-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | CYP2C9 2791/4885CCR1 2229/4885SMN1; SMN2 4715/4885 |
| US-10918622-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | CYP2C9 2791/4885CCR1 2229/4885SMN1; SMN2 4715/4885 |
| US-20200276162-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | CYP2C9 2791/4885CCR1 2229/4885SMN1; SMN2 4715/4885 |
| US-11826351-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | CYP2C9 2791/4885CCR1 2229/4885SMN1; SMN2 4715/4885 |
| US-10695323-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | CYP2C9 2791/4885CCR1 2229/4885SMN1; SMN2 4715/4885 |
| US-20230372298-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | CYP2C9 2791/4885CCR1 2229/4885SMN1; SMN2 4715/4885 |
| US-20210093611-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | CYP2C9 2791/4885CCR1 2229/4885SMN1; SMN2 4715/4885 |
| US-10464905-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | CYP2C9 2791/4885CCR1 2229/4885SMN1; SMN2 4715/4885 |
| US-10342780-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | CYP2C9 2791/4885CCR1 2229/4885SMN1; SMN2 4715/4885 |
| US-20190000806-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | CYP2C9 2791/4885CCR1 2229/4885SMN1; SMN2 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.